Phreesia’s (PHR) “Neutral” Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. restated their neutral rating on shares of Phreesia (NYSE:PHR) in a research report report published on Tuesday morning, Marketbeat Ratings reports. JPMorgan Chase & Co. currently has a $16.00 price objective on the stock, down from their prior price objective of $24.00.

A number of other equities analysts have also recently weighed in on PHR. Zacks Research cut shares of Phreesia from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Mizuho cut their target price on Phreesia from $22.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 24th. Truist Financial restated a “hold” rating and set a $11.00 price target (down from $24.00) on shares of Phreesia in a research note on Tuesday. Wall Street Zen cut Phreesia from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 8th. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $10.00 price objective (down from $25.00) on shares of Phreesia in a report on Tuesday. Twelve analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Phreesia Price Performance

NYSE:PHR opened at $8.35 on Tuesday. Phreesia has a one year low of $7.77 and a one year high of $32.76. The stock has a market cap of $503.18 million, a PE ratio of 278.20 and a beta of 0.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The stock has a 50 day moving average price of $12.07 and a 200 day moving average price of $17.44.

Phreesia (NYSE:PHR) last issued its earnings results on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). The firm had revenue of $127.07 million for the quarter, compared to analysts’ expectations of $126.75 million. Phreesia had a return on equity of 3.33% and a net margin of 0.48%.Phreesia’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period last year, the firm earned ($0.11) earnings per share. Equities research analysts expect that Phreesia will post -1.1 EPS for the current fiscal year.

Insiders Place Their Bets

In other Phreesia news, CFO Balaji Gandhi sold 8,009 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $136,233.09. Following the transaction, the chief financial officer directly owned 156,231 shares in the company, valued at $2,657,489.31. This represents a 4.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Linetsky sold 6,106 shares of the stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $103,863.06. Following the completion of the transaction, the insider directly owned 231,723 shares in the company, valued at $3,941,608.23. This trade represents a 2.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 70,358 shares of company stock worth $1,123,569. Insiders own 5.50% of the company’s stock.

Institutional Trading of Phreesia

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. raised its stake in shares of Phreesia by 2.7% during the 2nd quarter. Raymond James Financial Inc. now owns 14,049 shares of the company’s stock worth $400,000 after buying an additional 375 shares during the last quarter. Diversified Trust Co grew its stake in Phreesia by 1.7% in the 3rd quarter. Diversified Trust Co now owns 45,822 shares of the company’s stock valued at $1,078,000 after acquiring an additional 780 shares during the last quarter. Alliancebernstein L.P. grew its stake in Phreesia by 1.3% in the 3rd quarter. Alliancebernstein L.P. now owns 62,712 shares of the company’s stock valued at $1,475,000 after acquiring an additional 812 shares during the last quarter. Van ECK Associates Corp increased its holdings in Phreesia by 78.7% during the 4th quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock valued at $42,000 after acquiring an additional 1,102 shares in the last quarter. Finally, Arizona State Retirement System increased its holdings in Phreesia by 8.1% during the 3rd quarter. Arizona State Retirement System now owns 17,608 shares of the company’s stock valued at $414,000 after acquiring an additional 1,313 shares in the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Analyst take: a MarketBeat piece argues Phreesia may have hit a trough and is well‑positioned to regain growth and market share over time, suggesting upside if execution and demand stabilize. Phreesia Hits Bottom in Q1: Rebound Ahead, Timing Uncertain
• Neutral Sentiment: Several large firms have issued neutral/market‑perform ratings (Robert W. Baird, JPMorgan, Citigroup), signaling limited near‑term conviction rather than outright sell ratings. Phreesia (NYSE:PHR) Earns “Neutral” Rating from Robert W. Baird
• Neutral Sentiment: Citizens JMP reaffirmed a market‑perform view, reflecting tepid near‑term expectations from another sell‑side firm. Citizens JMP Market Perform Reaffirmed
• Neutral Sentiment: Investor comparison coverage contrasts Phreesia with peers (MSP Recovery), providing context but not a clear directional trigger. Phreesia and MSP Recovery Critical Contrast
• Negative Sentiment: Primary catalyst: Phreesia reported its first full‑year profit but issued lower FY2027 revenue guidance, prompting a sharp selloff as investors focused on the reduced top‑line outlook. Phreesia (PHR) Is Down 25.5% After First Full-Year Profit But Lower 2027 Revenue Guidance
• Negative Sentiment: Multiple analysts cut expectations and targets (Canaccord cut its price target to $22; Needham, Stephens and BMO issued more pessimistic views), increasing selling pressure and lowering implied valuation. Needham Lowers Expectations for Phreesia BMO Capital Markets Issues Pessimistic Forecast for Phreesia Needham & Company LLC Has Lowered Expectations for Phreesia
• Negative Sentiment: The stock hit a new one‑year low after the earnings/guide miss, a technical signal that can accelerate outflows from momentum and quant funds. Phreesia Reaches New 1-Year Low After Earnings Miss
• Negative Sentiment: Legal risk: a law firm announced an investigation into potential securities‑law violations tied to prior guidance comments, adding uncertainty and potential headline risk. Investors in Phreesia Warned of Potential Securities Fraud
• Negative Sentiment: Some outlets and analysts pulled recommendations or expressed disappointment in growth guidance, reinforcing negative sentiment. Phreesia’s growth guidance disappointed. We’re pulling our recommendation.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.